AACR: UT MD Anderson shares latest breakthroughs in cancer research

Cancer research · Esophageal cancer

Researchers used spatial transcriptomics to identify KDM2A as a key epigenetic driver of esophageal cancer progression

This article summarizes a series of abstracts presented by researchers from The University of Texas MD Anderson Cancer Center at the 2026 American Association for Cancer Research Annual Meeting. The abstracts cover advances in single‑cell technologies, integrative computational approaches, experimental therapeutics, targeted therapies, mechanisms of treatment resistance, cancer modelling, and emerging clinical trial results. Particular highlights include improvements in mRNA‑based vaccine‑enhanced immunotherapy, spatial multi‑omics characterisation of glioma microenvironments, a novel AI‑derived GRB2 inhibitor to overcome PARP resistance, a peptide‑linked antibody that redirects viral‑specific T cells to solid tumours, a digital twin model for ALK‑positive lung cancer, high‑fiber diet benefits for melanoma immunotherapy, an antibody‑drug conjugate active across multiple tumour types, and new therapeutic strategies to counter radiation and chemotherapy resistance in cervical and pancreatic cancers. The article is a press‑release‑style news briefing and does not present new experimental data beyond the summaries of the cited abstracts.

The conference abstracts represent cutting‑edge research from a leading cancer institute, illustrating the breadth of therapeutic and diagnostic innovations that may translate into improved patient outcomes. The highlighted findings span multiple tumour types and incorporate state‑of‑the‑art technologies, providing a snapshot of the translational trajectory from bench to bedside.

Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.

Original source

Related signals